Albyn Medical Limited - Period Ending 2019-09-30

Albyn Medical Limited - Period Ending 2019-09-30


Albyn Medical Limited SC128038 false 2018-10-01 2019-09-30 2019-09-30 The principal activity of the company is that of the sales and installation of medical systems and equipment within the UK Digita Accounts Production Advanced 6.24.8820.0 Software true SC128038 2018-10-01 2019-09-30 SC128038 2019-09-30 SC128038 bus:OrdinaryShareClass1 2019-09-30 SC128038 core:RetainedEarningsAccumulatedLosses 2019-09-30 SC128038 core:ShareCapital 2019-09-30 SC128038 core:SharePremium 2019-09-30 SC128038 core:CurrentFinancialInstruments 2019-09-30 SC128038 core:CurrentFinancialInstruments core:WithinOneYear 2019-09-30 SC128038 core:ConstructionInProgressAssetsUnderConstruction 2019-09-30 SC128038 core:FurnitureFittingsToolsEquipment 2019-09-30 SC128038 core:MotorVehicles 2019-09-30 SC128038 bus:SmallEntities 2018-10-01 2019-09-30 SC128038 bus:Audited 2018-10-01 2019-09-30 SC128038 bus:FullAccounts 2018-10-01 2019-09-30 SC128038 bus:SmallCompaniesRegimeForAccounts 2018-10-01 2019-09-30 SC128038 bus:RegisteredOffice 2018-10-01 2019-09-30 SC128038 bus:Director2 2018-10-01 2019-09-30 SC128038 bus:OrdinaryShareClass1 2018-10-01 2019-09-30 SC128038 bus:PrivateLimitedCompanyLtd 2018-10-01 2019-09-30 SC128038 core:ConstructionInProgressAssetsUnderConstruction 2018-10-01 2019-09-30 SC128038 core:FurnitureFittingsToolsEquipment 2018-10-01 2019-09-30 SC128038 core:MotorVehicles 2018-10-01 2019-09-30 SC128038 core:OfficeEquipment 2018-10-01 2019-09-30 SC128038 core:OtherRelatedParties 2018-10-01 2019-09-30 SC128038 countries:Scotland 2018-10-01 2019-09-30 SC128038 2018-09-30 SC128038 core:ConstructionInProgressAssetsUnderConstruction 2018-09-30 SC128038 core:FurnitureFittingsToolsEquipment 2018-09-30 SC128038 core:MotorVehicles 2018-09-30 SC128038 2018-09-30 SC128038 bus:OrdinaryShareClass1 2018-09-30 SC128038 core:RetainedEarningsAccumulatedLosses 2018-09-30 SC128038 core:ShareCapital 2018-09-30 SC128038 core:SharePremium 2018-09-30 SC128038 core:CurrentFinancialInstruments 2018-09-30 SC128038 core:CurrentFinancialInstruments core:WithinOneYear 2018-09-30 SC128038 core:ConstructionInProgressAssetsUnderConstruction 2018-09-30 SC128038 core:FurnitureFittingsToolsEquipment 2018-09-30 SC128038 core:MotorVehicles 2018-09-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: SC128038

Albyn Medical Limited

Financial Statements

for the Year Ended 30 September 2019

A9 Accountancy Limited
Chartered Accountants & Statutory Auditor
Elm House
Cradlehall Business Park
Inverness
IV2 5GH

 

Albyn Medical Limited

(Registration number: SC128038)
Balance Sheet as at 30 September 2019

Note

2019
£

2018
£

Fixed assets

 

Tangible assets

4

81,212

38,559

Current assets

 

Stocks

5

84,512

54,825

Debtors

6

322,433

329,078

Cash at bank and in hand

 

46,483

25,630

 

453,428

409,533

Creditors: Amounts falling due within one year

7

(220,156)

(209,726)

Net current assets

 

233,272

199,807

Total assets less current liabilities

 

314,484

238,366

Provisions for liabilities

431,079

231,102

Net assets

 

745,563

469,468

Capital and reserves

 

Called up share capital

8

2,701,654

2,701,654

Share premium reserve

19,761

19,761

Profit and loss account

(1,975,852)

(2,251,947)

Total equity

 

745,563

469,468

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the director on 11 February 2020
 

.........................................

Luis I Collantes
Director

 

Albyn Medical Limited

Notes to the Financial Statements for the Year Ended 30 September 2019

1

General information

The company is a private company limited by share capital, incorporated in Scotland.

The address of its registered office is:
Kintail House
Beechwood Park
Inverness
Highland
IV2 3WB
Scotland

These financial statements were authorised for issue by the director on 11 February 2020.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Audit report

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 11 February 2020 was Paul Capewell, who signed for and on behalf of A9 Accountancy Limited.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

Albyn Medical Limited

Notes to the Financial Statements for the Year Ended 30 September 2019

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Foreign Currency
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating profit.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Demonstration stock

33% - 100% straight line

Motor vehicles

25% straight line

Office equipment

20% - 33% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

 

Albyn Medical Limited

Notes to the Financial Statements for the Year Ended 30 September 2019

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company during the year was 6 (2018 - 6).

 

Albyn Medical Limited

Notes to the Financial Statements for the Year Ended 30 September 2019

4

Tangible assets

Office equipment
£

Motor vehicles
 £

Demonstration stock
£

Total
£

Cost or valuation

At 1 October 2018

56,535

45,255

226,354

328,144

Additions

1,621

14,690

59,627

75,938

Disposals

-

(8,692)

(104,312)

(113,004)

At 30 September 2019

58,156

51,253

181,669

291,078

Depreciation

At 1 October 2018

54,995

36,962

197,628

289,585

Charge for the year

920

4,835

23,190

28,945

Eliminated on disposal

-

(7,420)

(101,244)

(108,664)

At 30 September 2019

55,915

34,377

119,574

209,866

Carrying amount

At 30 September 2019

2,241

16,876

62,095

81,212

At 30 September 2018

1,540

8,293

28,726

38,559

5

Stocks

2019
£

2018
£

Other inventories

84,512

54,825

6

Debtors

Note

2019
£

2018
£

Trade debtors

 

230,835

87,197

Amounts owed by group undertakings and undertakings in which the company has a participating interest

9

91,598

235,478

Prepayments

 

-

6,403

 

322,433

329,078

 

Albyn Medical Limited

Notes to the Financial Statements for the Year Ended 30 September 2019

7

Creditors

Creditors: amounts falling due within one year

2019
£

2018
£

Due within one year

Trade creditors

39,350

58,543

Taxation and social security

34,861

34,833

Accruals and deferred income

13,314

15,676

Other creditors

132,631

100,674

220,156

209,726

8

Share capital

Allotted, called up and fully paid shares

 

2019

2018

 

No.

£

No.

£

Ordinary shares of £1 each

2,701,654

2,701,654

2,701,654

2,701,654

         

9

Related party transactions

Weist Uropower Limited
(Fellow subsidiary of Albyn Medical S.L.)
During the year the company made sales to Weist Uropower Limited totalling £Nil (2018: £200).

At the balance sheet date the amount due to Weist Uropower Limited was £Nil (2018: £Nil).

Summary of transactions with other related parties

Albyn Medical S.L.
(Parent company - a company registered in Spain)

 During the year, the company sold goods and services to the parent company amounting to £30,698 (2018: £70,969) and purchased goods and services from the parent company amounting to £595,733 (2018: £463,560).

Management charges totalling £43,399 (2018: £27,256) were charged to the company by Albyn Medical S.L.

During the year Albyn Medical Limited charged Albyn Medical S.L total interest of £1,346 (2018: £1,134).

At the balance sheet date the amount owed to Albyn Medical Limited was £91,598 (2018: £235,478).